Patents Examined by Niloofar Rahman
  • Use of EZH2 inhibitors for treating cancer
    Patent number: 11786533
    Abstract: The disclosure provides a method for treating cancer in a subject in need thereof comprising administering to the subject: (a) a therapeutically effective amount of an EZH2 inhibitor and (b) a therapeutically effective amount of an immune checkpoint inhibitor. In certain embodiments of the methods of the disclosure, the EZH2 inhibitor is tazemetostat.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: October 17, 2023
    Assignee: Epizyme, Inc.
    Inventors: Scott Ribich, Michael Thomenius
  • Indomethacin analogs for the treatment of castrate-resistant prostate cancer
    Patent number: 11738004
    Abstract: Provided are compositions for inhibiting a biological activity of an aldo-keto reductase family 1, member C3 (AKR1C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.
    Type: Grant
    Filed: April 21, 2021
    Date of Patent: August 29, 2023
    Assignees: Vanderbilt University, The Trustees of the University of Pennsylvania
    Inventors: Lawrence J. Marnett, Andy J. Liedtke, Trevor M. Penning, Adegoke O. Adeniji, Michael C. Byrns
  • Heterocyclic compounds as PRMT5 inhibitors
    Patent number: 11459338
    Abstract: The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: October 4, 2022
    Assignee: JUBILANT EPISCRIBE LLC
    Inventors: Saravanan Vadivelu, Sridharan Rajagopal, Raghunadha Reddy Burri, Shivani Garapaty, Dhanalakshmi Sivanandhan, Manish Kumar Thakur, Tamizharasan Natarajan, Indu N Swamy, Nagendra Nagaraju, Subramaniam Kanagaraj, Zainuddin Mohd, Sayantani Sarkar, Swapan Kumar Samanta, Hariprakash
  • Fused pentacyclic polyethers
    Patent number: 8609628
    Abstract: Disclosed are polycyclic polyether compounds of formula I and pharmaceutical compositions comprising such compounds. wherein R, OR1, and R2 are as defined herein. Also disclosed are methods of regulating mucus clearance in a cell, and methods of treating decreased mucus clearance or mucociliary dysfunction.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: December 17, 2013
    Assignee: University of North Carolina at Wilmington
    Inventors: Daniel G. Baden, William M. Abraham, Andrea J. Bourdelais, Sophie Michelliza